Recent Updates
Recently added Catalysts
IMMP Positive Sentiment Score: 75/100

Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast Cancer SYDNEY, AUSTRALIA

Thursday, October 3, 2024 2 min read
Key Takeaway: Immutep Limited has completed patient enrollment for the randomized Phase II portion of the AIPAC-003 clinical trial, focusing on metastatic breast cancer. The trial involves 65 patients who have exhausted other therapy options and will assess the efficacy of eftilagimod alpha in combination with paclitaxel. This research is pivotal in determining the optimal dosage and furthering treatment options for patients with breast cancer. Upcoming updates will follow after data collection and analysis.

Market Sentiment Analysis

POSITIVE FACTORS

  • Completion of patient enrollment marks a significant milestone for the AIPAC-003 trial.
  • The trial aims to explore innovative treatment options for metastatic breast cancer.
  • Collaboration across 22 clinical sites enhances the trial's comprehensive data collection.

Full Press Release Details

Immutep Completes Patient Enrolment in Randomised Phase II
of AIPAC-003 Trial in Metastatic Breast Cancer
SYDNEY, AUSTRALIA October 03, 2024 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a
clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces patient enrolment has been completed in the randomised Phase II portion of the AIPAC-003 (Active Immunotherapy and PAClitaxel) clinical trial.
The Phase II enrolled 65
metastatic hormone receptor positive (HR+), HER2-negative/low or triple-negative breast cancer patients who exhausted endocrine therapy including cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. Patients across 22 clinical sites in Europe and the
United States have been randomised 1:1 to receive either 30mg or 90mg dosing of eftilagimod alpha ( efti ) in combination with paclitaxel to determine the optimal biological dose consistent with the FDA s Project Optimus initiative.
Further updates will be provided after data collection, data cleaning, and analysis. For more information on the trial, please visit
clinicaltrials.gov (NCT05747794).
Immutep is a clinical-stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune
disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and our diversified product portfolio
harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information,
please visit www.immutep.com.
Australian Investors/Media:
Catherine Strong, Sodali & Co.
catherine.strong@sodali.com
Chris Basta, VP, Investor Relations and Corporate Communications
+1 (631) 318 4000; chris.basta@immutep.com
announcement was authorised for release by the CEO of Immutep Limited.
Immutep Limited, Level 32, Australia Square, 264 George
Street, Sydney NSW 2000, Australia

Frequently Asked Questions

What is the AIPAC-003 trial about?

The AIPAC-003 trial evaluates eftilagimod alpha in metastatic breast cancer patients.

How many patients were enrolled in the AIPAC-003 trial?

A total of 65 patients were enrolled for this clinical trial.

What types of breast cancer are being studied?

The trial focuses on metastatic HR+, HER2-negative/low, and triple-negative cases.

What is the purpose of the randomization in the trial?

Patients are randomized to identify the optimal dose of eftilagimod alpha.

Where can I find more information about the trial?

Further details can be found on clinicaltrials.gov under NCT05747794.

Tags: IMMP Viatris Investor Conferences Healthcare Immutep AIPAC-003 metastatic breast cancer eftilagimod alpha clinical trial
Last updated: Oct 3, 2024